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It is fitting that the Zollinger-Ellison syndrome (ZES) be included in the Lester
Dragstedt Symposium because Dr. Dragstedt had a long-time interest in this
disease, having been one of the five discussants of the original article and sub-
sequently reporting with Dr. Oberhelman on nine cases. The approach to thera-
py of ZES has been controversial from the beginning, and a number of contro-
versies remain. In this article, four different controversies are analyzed from the
prospective of the past (Zollinger-Dragstedt era, 1955-1980), present and what
may happen in the future in light of recent results. Specifically analyzed are: 1)
the role of gastric surgery in the management; 2) whether gastrinoma removal
without aggressive resection in patients with ZES without MEN-I is the pre-
ferred surgical therapy; 3) whether patients with MEN-I should undergo routine
surgical exploration; and 4) whether most gastrinomas will be localized preop-
eratively. An analysis of recent advances suggests there may be marked
changes in the future from our current and our past approaches.
INTRODUCTION
In 1955, Zollinger and Ellison described two female patients with a syndrome char-
acterized by the presence of primary peptic ulcerations in unusual locations such as the
distal duodenum or jejunum, gastric acid hypersecretion of gigantic proportion and the
presence of a nonspecific islet cell tumor of the pancreas [1]. It was subsequently shown
that this syndrome is due to the autonomous release of gastrin by the tumor and, thus,
they were called gastrinomas [2]. A number of other important aspects of the disease
have since been recognized [3]. Although older studies suggested gastrinomas were dis-
tributed in a 4:1:4 ratio in pancreatic head, body and tail [4], recent studies show that gas-
trinomas occur primarily (> 80 percent) in the duodenum-pancreatic head area [3, 5-7].
Currently, only 34 percent of patients have metastases at the time of diagnosis [3]; how-
ever, older studies suggest that up to 90 percent of gastrinomas are malignant [8].
Approximately 20 percent of patients with Zollinger-Ellison syndrome (ZES)b have it as
part of the multiple endocrine neoplasia-type I (MEN-I) syndrome [3], which is charac-
terized by autosomal dominant inheritance and hyperplasia or multiple adenomas in mul-
tiple endocrine organs (primarily hyperparathyroidism, 95-100 percent; pancreatic
endocrine tumors, 82 percent; and pituitary adenomas, 60 percent) [9]. Survival has been
shown to be related to control of the gastric hypersecretion, whether MEN-I is present or
not, tumor location and tumor extent [3]. The acid secretion can now be controlled with
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Table 1: Lester Dragstedt and Zollinger-Ellison syndrome.
I. 1955 One ofthe original five discussants ofZollinger and Ellison's original paper
[1]. Discussion included adescription of one case.
II. 1958 With Drs. H. A. Oberhelman and T. S. Nelson [11] description oftwo patients
with ZES treated with removal ofgastrinoma and gastric resection. Case one
was one ofthe first cases ofZES treated by total pancreatectomy.
III. 1961 With Drs. H. A. Oberhelman, T. S. Nelson, and A. N. Johnson [12] reported
experience with six cases ofZES. In four ofthe six cases complete resection of
the tumor with reduction in gastric secretion to normal was obtained.
IV. 1966 Experience with nine cases ofZES discussed in a symposium on gastrin [13].
potent antisecretory agents such as H+/K+-ATPase inhibitors (i.e., omeprazole, lansopra-
zole) both short- and long-term in all patients [3, 10].
It is fitting that this disease be included in the Lester R. Dragstedt Symposium
because Dr. Dragstedt had a long-term interest in the effect of the pancreas on gastric
secretion as well as in the Zollinger-Ellison syndrome (Table 1). He was one ofthe origi-
nal five discussants of the 1955 Zollinger and Ellison paper [1], presenting one case of
his own and in later presentations of studies done with Dr. Oberhelman, presenting data
with eight more cases and pointing out that it was one ofthe causes for failure ofa peptic
ulcer to heal after a vagotomy [11-14].
Zollinger-Ellison syndrome has been extensively reviewed recently [3, 15-17]. In
this paper, only certain controversial areas ofmanagement will be dealt with. Because of
the prospective it provides, I have elected to present these as questions analyzed in terms
of the past view (Zollinger-Ellison and Dragstedt era, 1955-1980), the view at present
and then what may happen in the future.
QUERY I: WHAT IS THE ROLE OF GASTRIC SURGERY IN THE
MANAGEMENT OF PATIENTS WITH ZES?
I-A, Past. Initially it was unclear whether attempted curative gastrinoma resection or
gastric surgery to remove or alter the responsiveness ofstomach should be done [1, 4, 13,
14]. Numerous early studies [3, 4] demonstrated that gastric acid hypersecretion could
only be reliably controlled by a total gastrectomy. Some early studies, including a study
by Dragstedt, showed that some patients became asymptomatic after resection ofthe gas-
trinoma only [11, 18, 19]. However, this treatment course was generally not pursued
because in most cases gastrinoma resection did not result in long-term cure, and if the
disease recurred, the acid hypersecretion led to life-threatening complications.
I-B, Present. Currently, the reverse situation from the past is recommended. Gastric
acid surgery is recommended only in patients who cannot or will not take gastric antise-
cretory agents [3, 20]. With the recent availability of potent gastric acid antisecretory
agents, particularly the H+/K+-ATPase inhibitors, omeprazole or lansoprazole, hyper-
secretion can now be controlled medically (Table 2). The H+/K+-ATPase inhibitors have a
long duration of action in contrast to the histamine H2-receptor antagonists, making once
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Table 2. Results from studies of long-term medical control of gastric hypersecretion in
patients with ZES.
Principal antisecretory No. of(a) Mean Duration % Failure Author, Year, Reference
drug(s) patients oftreatment
(mo)
Histamine H2-receptor
antagonist
Cimetidine 13 61 Bonfils et al., 1979 [21]
14 11 0 Stage et al., 1979 [22]
17 26 65 Deveney et al., 1983 [23]
Cimetidine plus
anticholinergic agent 61 12 8 McCarthy, 1978 [24]
12 33 65 Stabile et al., 1983 [25]
18 29 6 Malagelada et al., 1983 [27]
Ranitidine 15 18 40 Mignon et al., 1982 [27]
Ranitidine plus
anticholinergic agent 19 14 0 Jensen et al., 1984 [28]
Famotidine alone or with
anticholinergic agent 32 10 0 Vinayek et al., 1986 [29]
H+/K+-ATPase inhibitor
Omerprazole 40 29 0 Maton et al., 1989 [30]
80 19 8 Lloyd-Davies et al., 1988 [31]
31 ND 3 Hirschowitz et al., 1988 [32]
22 27 0 Bardram et al., 1989 [33]
20 16 0 Cadranel et al., 1989 [34]
116 38 0 Metzetal., 1993 [35]
Lansoprazole 21 31 0 Jensen et al., 1993 [36]
28 18 0 Hirschowitz, 1993 [37]
(a) Only series that include at least 13 patients are included.
or twice a day dosing possible [10]. In contrast to the older studies with histamine H2-
blockers (Table 2) [21-29], gastric acid hypersecretion has been able to be controlled in
all patients [30-37]. A recent study reports omeprazole also is effective long-term with
patients treated up to nine years without loss of control or toxicity [35]. Furthermore, a
recent study demonstrates the daily dose of omeprazole can be reduced to the same dose
used in patients with idiopathic duodenal ulcer disease (i.e., 20 mg., daily) in 95 percent
of patients with uncomplicated diseases (no MEN-I, previous gastric surgery or severe
reflux disease) [38]. Therefore, at present, oral gastric antisecretory agents are convenient
and effective in all patients who will take the medication, and total gastrectomy is not rec-
ommended.
I-C, Future. It is likely that in the future two forms of gastric surgery may be impor-
tant in the management ofpatients with ZES. A recent study (Figure 1) demonstrates that
postcurative gastrinoma resection, BAO and MAO decrease within three to six months by
75 percent and 50 percent, respectively [39]. However, long-term (up to four years) 67
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Figure 1. Effect ofcurative gastrinoma resection on basal acid output. Basil acid output (BAO)
was measured before and up to four years after curative resection of 17 patients. Data for men
(n=9) and women (n=8) are shown in the left and right panels, respectively. The dotted line repre-
sents the upper limit of normal for BAO for men (10 mEq/hr) and women (5.6 mEq/hr). Data are
from Ref. 37.
percent of patients remained mild gastric hypersecretors, and 40 percent required low
doses of ranitidine [39, 40]. Routine parietal cell vagotomy for patients with ZES has
been recommended in the past [18]; however, a number of authorities have questioned
this [1, 20], and it is now infrequently performed. A recent preliminary report of the
patients in the above study [41] showed, on long-term follow-up (average, 10 years) post-
parietal cell vagotomy, that these patients without tumor resected show an average
decrease of 75 percent in basal acid output. Ifthe routine addition ofparietal cell vagoto-
my to curative gastrinoma resection could be shown to result in most patients not requir-
ing any gastric antisecretory drug, then this procedure may be routinely performed in
those patients undergoing exploration for possible gastrinoma resection in the future.
Recent studies in animals demonstrate that chronic hypergastrinemia causes
increased numbers ofgastric enterochromaffin-like cells (ECL cells) and a progression in
changes in ECL cells from hyperplasia (simple diffuse to linear, to micronodular, to ade-
nomatoid) to dysplasia and finally to the carcinoid stage. Some gastric carcinoid tumors
are malignant [3, 42-44]. Previous studies have reported gastric carcinoid tumors in
patients with ZES and that the ECL cells are increased, usually two- to three-fold [43, 45,
46]. In a recent study of patients with ZES without MEN-I, ECL cells showed a normal
pattern in 16 percent ofpatients; 71 percent showed a simple diffuse hyperplasia; and 13
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percent showed a linear hyperplasia [47]. In patients with ZES with MEN-I, 53 percent
showed diffuse hyperplasia; 47 percent showed linear hyperplasia; and six percent had
areas of dysplasia [47]. Until recently, most patients underwent total gastrectomy, so that
there are only limited numbers ofpatients to assess the long-term risk of developing gas-
tric carcinoid tumors. However, with the availability of potent oral gastric antisecretory
agents, two groups have recently reported such data. In patients with ZES and without
MEN-I, in one study from the NIH of 160 patients, 0.6 percent (one patient) had a gastric
carcinoid [46]; whereas in the other study (31 patients), 0 percent had a gastric carcinoid
[47]. In contrast, in patients with ZES with MEN-I, in one study from the NIH of forty
patients, 13 percent had gastric carcinoids [46]; whereas in the other study (17 patients),
30 percent had gastric carcinoids [47]. An additional single patient with ZES without
MEN-I with a gastric carcinoid tumor has been reported [48]. These data demonstrate
that gastric carcinoids occur in both patients with ZES with or without MEN-I and that
genetic factors are important in determining the frequency. In a patient with ZES without
MEN-I, the risk appears to be quite low; whereas in patients with ZES with MEN-I, it is
at least 30-fold higher. Recent genetic studies show allelic loss on chromosome 11q13 in
parathyroid and pancreatic tumors in patients with MEN-I [49, 50], suggesting the MEN-
I gene functions as a tumor suppressor gene. Furthermore, a recent study shows loss of
heterozygosity in a gastric carcinoid tumor from a patient with MEN-I [51], suggesting
these tumors result from inactivation of two copies of the MEN-I gene, providing a basis
for the genetic contribution to gastric carcinoids in these patients. It has been estimated
that 10 percent of these gastric carcinoid tumors in hypergastrinemic patients are malig-
nant [44]; however, this is based on small numbers ofpatients with limited follow-up. At
present, the true percentage of patients with ZES who develop gastric carcinoids or the
percentage malignant is unclear. This has occurred because of the small numbers of
patients evaluated and because it is unclear what percentage of these tumors are detected
or the extent of invasiveness evaluated by routine endoscopy and biopsy. With total gas-
trectomy now not routinely done, increasing numbers of patients with ZES will be found
to have gastric carcinoids and in the future it is likely that surgical resection of some of
these will be increasingly considered. It will need to be defined how frequently they are
malignant and at what state surgical resection should be considered.
In summary, in the future it is likely a group ofpatients will be defined who will ben-
efit from routine parietal cell vagotomy, and gastric surgical procedures may be needed
for some patients with gastric carcinoid tumors.
QUERY II: WILL GASTRINOMA REMOVAL WITHOUT AGGRESSIVE
RESECTION (WHIPPLE'S) BE THE OPERATION OF CHOICE IN PATIENTS
WITH ZES AND WITHOUT MEN-I?
II-A, Past. As discussed in I-A., in early studies, curative resection of the gastrinoma
was rarely accomplished [5-7, 22, 26, 52-59] (Table 3). Furthermore, because of the need
to adequately control the gastric hypersecretion, total gastrectomy was the primary proce-
dure done, and the tumor resection received less emphasis [4]. Two exceptions to this are
the 25-year results of Friesen reported in 1982 [60] and the studies ofexcision of duode-
nal gastrinomas reported by Oberhelman in 1972 [19]. Friesen reported a relatively high
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Table 3. Percentage ofpatients with Zollinger-Ellison syndrome surgically cured in
different series.
Percent with normal
No. ofpatients(a) serum gastrin
operated postoperatively Author, year, reference
25 4 Stage et al., 1979 [22]
42 5 Zollinger et al., 1980 [53]
32 6 Bonfils et al., 1981 [54]
28 22 Wilson et al., 1982 [55]
26 12 Thompson et al., 1983 [56]
52 12 Deveney et al., 1983 [52]
44 16 Malagelada et al., 1983 [26]
45 11 Stabile et al., 1984 [5]
29 43 (immed. post op)(b) Norton et al., 1986 [6]
30 (6 mo-4yr)
125 26 Mignon et al., 1986 [57]
60 17 Ellison et al., 1987 [58]
43 27 Delcore et al., 1989 [59]
73 58 (3 mo)(b) Norton et al., 1992 [7]
73 30 (5 yr)
(a) Included are the results ofattempted surgical cure from series with at least 25 patients undergo-
ing surgical exploration.
(b) Refers to time ofevaluation postoperatively.
rate of 39 percent having normal fasting gastrins postresection [60] in 23 patients under-
going total gastrectomy and removal of all resectable tumor. However, it is not apparent
how many of these patients had serial provocative tests and how long the follow-up was
in each patient. Oberhelman [19] reported follow-up in 11 cases with duodenal tumors all
treated by tumor excision and only one patient also undergoing total gastrectomy.
Excellent symptomatic results were maintained for two to 11 years without a need for
total gastrectomy.
Il-B, Present. At present, removal ofthe tumor by enucleation in the pancreatic head,
resection, or enucleation in the pancreatic body or tail and resection in the duodenum is
the recommended procedure ofchoice for patients with ZES without MEN-I [3, 61]. The
role of a Whipple procedure at present is controversial. Because of the excellent long-
term prognosis ofpatients even with lymph node metastases [62, 63], it is, at present, not
generally used. However, some groups are increasingly considering it, especially in
selected patients with ZES and MEN-I [64-66] who have a family history of aggressive
disease and frequently have multiple gastrinomas in the duodenum. Results of recent
series report cure rates significantly better than the 12-25 percent reported in the past with
some series reporting rates greater than 50 percent (Table 2).
II-C, Future. A number ofpoints suggest that in the future the approach may be dif-
ferent from the present. First, the true long-term cure rate is at present not clear and is
likely significantly lower than a number of the studies in Table 2 suggest [6, 7, 57-59]. A
recent study [67] demonstrates that to detect all recurrences after resection, both fasting
gastrins and secretin provocative tests must be performed on a regular basis because nei-
ther alone detected all recurrences. Furthermore, in many of these studies, the follow-up
time is relatively short, and a recent NIH study shows that there is a steady relapse rate up
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Table 4. Preoperative localization of the gastrinoma in patients with Zollinger-Ellison
Syndrome.
% Positive in recent NIH surgical seriesa (range in other series)b
All Patients Duodenal
Gastrinomas
Imaging Study:
Ultrasound 19 (21-28) 4
CT scan 28 (35-59) 12
Angiography 59 (35-68) 46
MR imaging 25 (21-25) 20
Functional Study:
Portal venous sampling 73 (46-94) 77
(a) % Positive in Recent NIH Surgical Series refers to the percentage ofpatients considered for
surgical exploration (no liver metastases) in which the indicated test was positive.
From Refs. 3, 6, 67-79, 72, 84-88
(b) Range ofresults reported in various series. From Refs. 3, 6, 7, 83, 87.
to five years [7]. The NIH study involving 73 patients reported in 1992 [7] is both long-
term (up to nine years), and both fasting gastrin and secretin provocative tests were per-
formed yearly in all patients. This study [7] demonstrated an immediate postoperative
normalization of serum gastrin and secretin tests in 58 percent ofpatients and a five-year
cure rate of 30 percent. These data suggest that at present less than one-third of patients
are cured long-term, and if it is to be improved in the future, it is likely the surgical
approach may have to be modified. Second, a recent NIH prospective study demonstrates
that with the use ofroutine duodenotomy an additional 56 percent more duodenal tumors
can be detected than with the use ofpalpation after duodenal Kocherization and operative
ultrasound [68]. However, even with the use of all procedures including duodenotomy,
which resulted in finding tumors in 93 percent of all patients, the immediate postopera-
tive cure rate increased only slightly (i.e., from 50 to 62 percent) [7]. One important rea-
son for this minimal increase in patients without any evidence of disease immediately
postresection was that the increased numbers of tumors found were due to increased
numbers of duodenal tumors [7]. In contrast to older studies that suggested these were
more frequently benign than pancreatic tumors, 55 percent ofall the duodenal tumors had
metastases to regional lymph nodes [3, 7, 60, 68, 69]. These results suggest that the older
concept of duodenal gastrinomas being entopic and less malignant whereas pancreatic
gastrinomas are ectopic and more frequently malignant is not correct [3, 69-71]. Third,
even though the duodenal tumors have at least as high a metastatic rate to lymph nodes as
pancreatic gastrinomas, their metastatic rate to the liver is low [69].
With the high frequency of local lymph node metastases with duodenal tumors
resulting in a 30 percent long-term cure by simple resection, it is likely in the future
increased consideration of a Whipple procedure in selected cases will occur. This
approach will be further considered because of the sensitivity of functional localization
studies such as percutaneous transhepatic sampling for gastrin concentrations of portal
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venous tributaries or the newer technique of hepatic venous sampling for gastrin content
after selective intraarterial secretin injections [66, 72]. This latter technique has proved
very sensitive for localizing gastrinomas to the pancreatic head/duodenal area [72] (Table
4, Figure 3). Therefore, if only a positive lymph node is found in the pancreatic head area
at surgery as occurs now in 20 percent of all cases, coupled with functional localization,
there will likely be an increased tendency to do a Whipple procedure. Already a few
groups have advised it be considered in similar situations [64-66]. At present, with the
available data, such an aggressive approach is unwarranted. Patients with only lymph
node metastases have an excellent long-term survival that is not significantly different
from that in patients with completely resected tumors in a number ofstudies [62, 63]. For
a Whipple procedure to be recommended, it needs to be shown that the performance of a
Whipple operation can improve survival rate, or a subgroup of patients with a worse
prognosis needs to be identified in which this operation could bejustified. A recent DNA
flow cytometry study [73] demonstrates that the DNA pattern seen is an independent pre-
dictor of tumor behavior. However, flow cytometry needs to be done in more patients to
verify its predictive value. If verified, a method would have to be developed that would
allow flow cytometry to be used as a rapid procedure in the surgical setting. Additionally,
if either serological or tissue predictors of poor prognosis can be identified, then the
appropriateness of such aggressive surgery may bejustified.
In summary, in the future it is likely even more aggressive surgery will be indicated
on a subset of patients.
QUERY III: SHOULD PATIENTS WITH ZES WITH MEN-I UNDERGO
ROUTINE SURGICAL EXPLORATION FOR POSSIBLE
CURE OF THE GASTRONOMA?
Ill-A, Past. Although the MEN-I syndrome was described in 1954, this syndrome
was reported in 1964 in a review of 260 patients with ZES to occur in only 3 percent [4].
It is now clear that at least one of the two original patients with ZES reported by
Zollinger and Ellison [1] had ZES with MEN-I because one patient had a sister with an
insulinoma. Subsequent studies clearly demonstrated that MEN-I syndrome occurs in
approximately 20 percent of patients with ZES. In the past, the presence of MEN-I did
not significantly change the surgical management because all patients underwent total
gastrectomy and in some centers, simultaneous excision of all resectable tumor whether
MEN-I was present or not.
III-B, Present. At present the role of surgery to possibly cure patients with MEN-I is
controversial. In the last 10 years, it became increasingly clear from a number ofsurgical
studies that patients with ZES with MEN-I were not cured by simple tumor enucleation
[3]. In one review, 0 of 37 cases were cured by simple tumor enucleation [74]. Pathology
studies demonstrated that these patients frequently had multiple small microscopic adeno-
ma in addition to large tumors, and this failure to cure these patients was thought due to
an inability to remove all microadenomas that might be secreting gastrin [74, 75]. It was
therefore suggested by most investigators that these patients not undergo routine laparoto-
my for cure. Additional data used to support this conclusion were that, in some studies,
these patients had a significantly better prognosis than patients without MEN-I [3].
Although in the past a localized gastrin gradient by selective portal venous sampling or
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elevated serum pancreatic polypeptide level had been reported to be useful in identifying
patients to explore, recent studies show these investigations are not helpful [3, 76, 77]. At
present most groups recommend that patients with MEN-I with ZES not undergo routine
attempts at curative resection; however, some recommend it be done in selected patients
and an occasional group [78] suggest all such patients should be considered for curative
resection.
III-C, Future. In the future, the approach of not routinely exploring these patients for
possible cure may change. A recent study [78] reported that of eight patients with ZES
and MEN-I, gastrinomas were found in the proximal duodenum in all. In three patients
solitary tumors were present; in five patients multiple microadenomas were found; and in
four patients paraduodenal lymph nodes were involved. In contrast, only one ofthe seven
tumors found in these patients in the pancreas stained for gastrin. In four of six patients
the gastrin values returned to normal postoperatively, and these patients were thought
cured [78]. This study raises the possibility that the gastrinoma is almost always in the
duodenum and potentially curable. It therefore raises the question of whether these
patients should thus also undergo routine surgical exploration. It is not apparent from this
study that these patients can be cured by simple enucleation ofduodenal tumors because
two of the four patients with normal gastrins were post-Whipple resection. Furthermore,
it is not apparent the patients were actually cured by the procedures done or for how long
they were cured. Secretin provocative tests were not performed on these patients. A num-
ber of patients have been reported with normal fasting gastrin concentrations postopera-
tive, but with secretin provocation, the presence of a gastrinoma can be determined [67].
The patients in this study did not have secretin tests routinely and regularly performed
after surgery. Lastly, many of these patients underwent parathyroidectomies (seven of the
eight), and an effective parathyroidectomy has been shown to decrease fasting gastrin
values to normal and even cause the secretin provocative test to revert to normal in
selected patients with MEN-I and ZES [79]. Furthermore, studies by others have shown a
higher percentage of the pancreatic tumors staining positively for gastrin [75, 80]. These
results raise the possibility that these patients will not be curable without a Whipple
resection because of the multiple tumors and frequent metastases to lymph nodes (at pre-
sent, as discussed in II-C). Future, it is not established that this procedure will improve
survival.
Two additional points are likely to be important in the future in determining whether
surgical exploration should be undertaken. First, patients with ZES with MEN-I have a
30-fold higher incidence of gastric carcinoid tumors, and it is likely that both the genetic
factors (loss ofheterozygosity of the MEN-I locus on chromosome 11q13 in gastric carci-
noid tumors) and hypergastrinemia are contributing. If these gastric carcinoids are found
to be more malignant than the 10 percent proposed on studies from a small number of
patients [44], then the importance of rendering these patients normogastrinemic may
increase. Second, recent studies suggest that pancreatic endocrine tumors in patients with
MEN-I with ZES are not less malignant than in patients with ZES without MEN-I [3].
Therefore, increasingly in these patients, long-term survival will require treatment of the
tumor itself. One study has suggested that patients with pancreatic endocrine tumors
undergo exploration and enucleation of the tumors if they are imaged and larger than 2.5
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Figure 2. Comparison of the Ability of CT scanning (top panel) or MR imaging (STIR
sequence) (lower panel) to localize gastrinoma metastatic to the liver in a patient with
Zollinger-Ellison syndrome. CT scanning did not demonstrate any metastatic lesions in the liver,
whereas the STIR sequence (MR imaging) demonstrates a metastasis in the left lobe.
Abbreviations: T, tumor.
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to 3 cm [77]. Using this approach, three of six patients explored were found to have
malignant tumors although in no case was the patient cured of the ZES postresection
[77]. This approach is based on the premise that pancreatic endocrine tumors are histo-
logically and pathologically indistinguishable from carcinoid tumors, and in a number of
tissues, the malignant potential of carcinoid tumors has been shown to be dependent on
the size of the tumor [9]. No such data yet exist for pancreatic endocrine tumors.
However, because these patients all have numerous microadenomas, it is not possible to
completely remove all adenomata without a total pancreatectomy. To routinely operate
and even possibly cure the ZES by a lesser operation may not extend life because many
of the other tumors that exist in other parts of the pancreas, such as pancreatic polypep-
tide producing tumors (PPomas), are also frequently malignant [81]. While a total pancre-
atectomy [82] has been performed in an occasional patient with a family with a poor
prognosis, it is not generally recommended. The strategy to use in treating other common
pancreatic endocrine tumors that these patients develop, such as PPomas or nonfunction-
ing endocrine tumors [9, 81], is even less clear than that used to possibly treat the gastri-
noma.
In the future, it is likely it will be clearly defined whether patients with MEN-I with
ZES will be cured by enucleation ofduodenal gastrinomas. It is also likely that subsets of
patients may be identified who could benefit by surgical exploration.
QUERY IV: WILL MOST GASTRINOMAS BE LOCALIZED
PREOPERATIVELY BY IMAGING OR OTHER LOCALIZATION STUDIES?
IV-A, Past. In the past, the primary tumor was almost never localized by upper GI
X-rays or by the limited localization methods available [4]. Ultrasound, arteriography,
and later, CT scanning localized a small number ofthe primary tumors [3].
IV-B, Present. The present abilities of various methodologies to localize the primary
gastrinoma are summarized in Table 4. Even though the angiography is reported positive
in up to 68 percent of cases and CT scan in 50 percent in various series, at the NIH, the
CT scan is positive in only 28 percent and angiography in 59 percent ofpatients undergo-
ing laparotomy (Table 4). In many cases, these results do not present true localization of
the primary tumor because they are not identifying the primary tumor but instead, lymph
node metastases, particularly in the pancreatic head area. In a recent study the combina-
tion of ultrasound, CT scan and angiography localized a tumor in 52 percent of the cases
[7]. However at surgery, 20 percent of the patients had only gastrinoma found in lymph
nodes. Furthermore, duodenal gastrinomas are usually less than 1 cm in diameter [7, 69,
83], and imaging studies usually do not localize tumors ofthis size [84, 85] (Table 4). Of
these studies, selective angiography remains the procedure of choice to localize the pri-
mary tumor [3, 84, 86]. For the primary gastrinoma, MR imaging, with or without
gadolinium, is equally sensitive to ultrasound but significantly less sensitive than angiog-
raphy [86] (Table 4).
Functional localization by portal venous sampling (PVS) and the newer technique of
hepatic venous sampling for gastrin levels after intraarterial secretin injection localize
almost 90 percent of all gastrinomas [69, 87, 88] (Table 4, Figure 3). A typical example of
both studies in one patient is shown in Figure 3. The portal venous sampling demonstrates
a positive gastrin gradient of 1100 percent in the pancreatic head area. Hepatic venous
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Figure 3. Ability to functionally localize the gastinoma by determination ofserum gastrin gra-
dients after intraarterial secretin injection (top panel) or transhepatic portal venous sampling
(bottom panel). Top panel: Hepatic venous samples were obtained before 30, 60 and 120 sec after
the selective injection of secretin (30 units) into the gastroduodenal, superior mesenteric and
splenic artery. A positive gradient (.50% at 30 sec .100% at 60 sec) [68] is seen only with the gas-
troduodenal injection localizing the tumor in the pancreatic head/duodenal area. Bottom panel:
Results are from the same patient as in the top panel. Values are the serum gastrin concentration at
the indicated location with a simultaneous peripheral venous value of 200 pg/ml. A positive gastrin
gradient [83, 84] of 1100% = [(2400-200/200]xlOO exists in the superior pancreaticoduodenal vein
draining the pancreatic head area [83]. In the area indicated by the black dot, a 0.5 cm gastrinoma
was was found. Abbreviations: PV, portal vein; SPDV, superior pancreaticoduodenal vein; IPDV,
inferior pancreaticoduodenal vein; SMV, superior mesenteric vein; GCV, gastrocolic vein; TPV,
transverse pancreatic vein; SV, splenic vein; SMA, superior mesenteric artery.
sampling after selective intraarterial injection of secretin (IAS) demonstrates a positive
increase only after injection into the gastroduodenal artery which serves the pancreatic
head area. At surgery, this patient had a 0.5 cm duodenal wall tumor. In a recent compara-
tive study [72], the IAS was more sensitive than PVS and was particularly sensitive in
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patients with duodenal tumors, with 80 percent ofpatients with duodenal tumors having a
positive gastroduodenal injection with IAS and only 30 percent of the patients having a
positive PVS. Unfortunately, these functional localization studies only localize to the area
(i.e., pancreatic head/duodenum, body, tail) and do not discriminate exactly where in the
area the tumor is. Nevertheless, these studies may be useful in the future if a Whipple
procedure is being considered.
In contrast to the primary tumor, almost all patients with metastatic disease to the liv-
er can be recognized by a combination of imaging studies [3, 84]. In one prospective
study [84], the combination of CT scanning and angiography identified greater than 95
percent of patients with metastatic liver disease. A recent study [86] demonstrates that
recent improvements in MR imaging have greatly improved its sensitivity, such that it
now has an even greater sensitivity than angiography (83 percent vs. 61 percent) in iden-
tifying liver metastases. The metastases are particularly well seen on the STIR (short-
term inversion recovery magnetic resonance image) [86] as shown in Figure 2. In this
patient the hepatic metastasis was not seen on CT scan (without [Figure 2, top], or with
intravenous contrast); however, it was easily seen with the STIR MR image (Figure 2,
bottom).
Therefore at present, imaging studies (CT, ultrasound, MR imaging, angiography)
localize less than 50 percent ofprimary gastrinomas and miss most small duodenal gastri-
nomas (Table 4). Functional localization studies (i.e., venous gastrin sampling) localize
more frequently (Table 4) but are only region-specific (i.e., pancreatic tail, head, etc.) [87,
88]. For metastatic gastrinoma to the liver, imaging studies, especially MR imaging in
combination with the other studies, will localize almost all patients with liver metastases.
Thus, there is a need for better localization studies particularly for the primary tumor.
Recently, newer techniques have been described such as endoscopic ultrasound [89, 90],
MR imaging with dynamic gadolinium enhancement and fat suppression [91] and
radionuclide scanning after injection of radiolabeled octreotide, a somatostatin-octapep-
tide analogue [92, 93]. These will be dealt with briefly in the next section.
IV-C, Future. In the future, the newer techniques ofendoscopic ultrasound, the use of
radiolabeled somatostatin analogues and improved MR imaging may enhance preopera-
tive localization. Endoscopic ultrasound has recently been seen to be particularly sensi-
tive for localizing pancreatic endocrine tumors [89, 90]. In one study of 31 patients with
various pancreatic endocrine tumors with negative CT scans and ultrasound studies,
endoscopic ultrasound localized 82 percent of the tumors found at surgery. Endoscopic
ultrasound was also significantly more sensitive than angiography (82 percent vs. 27 per-
cent) [89]. However, as pointed out in an editorial to one of these studies [94], it is not
clear that this technique will localize small duodenal gastrinomas. Furthermore, its true
false-positive rate has not been carefully studied. Nevertheless, the current data suggest
endoscopic ultrasound will localize most pancreatic gastrinomas and may replace some
ofthe other older imaging studies.
Pancreatic endocrine tumors as well as a number of other tumors (breast cancer,
small cell lung cancer, CNS tumors, lymphomas) frequently possess high densities of
somatostatin receptors that can be used to localize these tumors [92, 95-100]. Both
[125I-Tyr3] octreotide and [11In-DTPA-DPhe'] octreotide have been used for localization
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[97]. Radiolabeled octreotide scanning has been reported to localize pancreatic endocrine
tumors not identified by other methods [92]. In one comparative study of23 patients with
sporadic gastrinoma without known metastases by other localization methods, radiola-
beled somatostatin scintography demonstrated in 52 percent ofpatients areas ofincreased
uptake at sites not known to contain tumors [100]. It is reported to localize the pancreatic
primary tumor and their metastases in 80 percent ofcases [93]. In another recent study, it
localized gastrinomas in all 13 patients studied and was more sensitive than other imag-
ing studies [101]. However, at present, experience with this technique is limited to a few
centers and it has not been prospectively studied carefully. It is likely it will prove partic-
ularly useful for identifying metastases to bone or lymph nodes in areas that might not
ordinarily be carefully imaged. This would suggest it may be particularly important to
assess disease extent. Its role in localizing small duodenal gastrinomas at present is
unclear.
The sensitivity of MR imaging for pancreatic endocrine tumors is rapidly increasing
with recent improvements. A recent study compared MR imaging results in 1993 to MR
imaging results from 1985-1987 [86] in patients with ZES at the same institution and
demonstrated that the sensitivity for detection of hepatic metastases had increased to 83
percent from 43 percent. This study [86] concluded that MR imaging was now the imag-
ing procedure ofchoice for identifying hepatic metastases. In this study [86] the sensitivi-
ty for primary gastrinomas did not change (25 percent, 1993 vs. 20 percent, 1985-1987).
However, another recent study [91] in 11 patients with pancreatic endocrine tumors
reported localization with MR imaging with dynamic gadolinium enhancement and fat
suppression in all patients. Two tumors (a gastrinoma and insulinoma) were less than 1
cm in diameter and detected by this methodology [91]. These results suggest further
improvements in MR imaging may lead to increased sensitivity for detection of even
small gastrinomas in the future.
In summary, these preliminary results suggest that the ability to detect primary gas-
trinomas preoperatively will continue to improve in the future, although it still remains
unclear whether any of these procedures has sufficient sensitivity to detect small duode-
nal gastrinomas.
V. OTHER QUERIES
There are a number of additional queries that could have been dealt with but will be
only briefly discussed here.
V-A, Will the time to diagnosis improvefurther and result in increased survival? In
recent studies [3], the time from the onset of continuous symptoms to diagnosis remains
five to six years. At present, 34 percent ofpatients have metastatic disease to the liver at
the time ofdiagnosis [3]. This latter group ofpatients has a poor prognosis [3], and there-
fore, ifsurvival is to be markedly improved, earlier diagnosis is needed. Understanding of
the natural history of gastrinoma is limited, and it is not clear whether even earlier diag-
nosis will recognize more patients without metastatic disease. A recent study [58] sug-
gests this will be possible because 56 percent ofpatients seen at one center before gastrin
RIA's had liver metastases and only 23 percent after their introduction. Furthermore, the
cure rate increased from four percent to 30 percent, suggesting an earlier state of disease
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was being seen. With increased awareness of the disease it would be hoped earlier diag-
nosis may occur. However, potent gastric antisecretory agents such as omeprazole may
actually delay the diagnosis. Omeprazole will control gastric acid secretion in most
patients with ZES with the recommended doses used for idiopathic peptic ulcer disease
and thus, the response to antisecretory therapy will not be a discriminating feature as it
was with histamine H2-receptor antagonists which did not control gastric secretion ade-
quately in ZES patients with conventional doses [28, 102].
V-B, Will a group ofpatients having only lymph nodeprimary gastrinomas be identi-
fied? At present, approximately 20 percent of patients are found to have gastrinoma only
in lymph nodes, usually in the pancreatic head area [7]. A number of these patients in dif-
ferent studies [5, 7, 55, 60, 63, 65, 83] have had long-term cures postresection, and it has
raised the possibility that gastrinomas may originate in lymph nodes in some cases. The
cell of origin of gastrinomas remains unclear, and therefore at present, this issue remains
controversial. With more extensive surgery and additional insights into the cellular ori-
gins of gastrinomas, this issue will likely become clearer in the future.
V-C, How will patients with advanced disease with liver metastases be more effec-
tively treated in the future? The current recommended treatment is chemotherapy with
streptozotocin and doxorubicin with or without 5-fluorouracil [3, 9, 103]. At present, the
true response rate in metastatic gastrinomas and its benefit remain not completely clear.
In a study [103] of patients with metastatic disease due to different types of endocrine
tumors including gastrinomas, 69 percent of patients responded to streptozotocin plus
doxorubicin and 46 percent to streptozotocin plus fluorouracil (p = .05) and the length of
time to tumor progression was longer with streptozotocin and doxorubicin (median 20 vs.
6.9 mos, p = .001). Streptozotocin plus doxorubicin in this study [103] also had a signifi-
cant survival advantage. However, in two other studies entirely on patients with metastat-
ic gastrinoma, the response rate was five percent with streptozotocin and fluorouracil in
one [104] and 40 percent with streptozotocin, fluorouracil and doxorubicin in the other
[105] and did not result in increased survival in responders versus nonresponders in one
study [105]. Furthermore, this chemotherapeutic regimen is associated with significant
toxicity, especially streptozotocin-induced nephrotoxicity. Treatment with a-interferon
has been reported to be effective in patients with gastrinomas and other metastatic islet
cell tumors [9, 106]. However, in a recent prospective study [107] in 13 cases with
metastatic gastrinoma, no patient had a decrease in tumor size; in 30 percent, the tumor
remained stable for a variable time, and it was concluded that a-interferon alone was not
of benefit in these patients. The somatostatin analogue, octreotide, has also been reported
to be useful in endocrine tumors, particularly carcinoid tumors which histologically
resemble gastrinomas [9]. However, a preliminary report [108] from a large European
study reports that octreotide did not decrease metastatic tumor size in any of the 25
patients treated (including six with metastatic gastrinoma). In this study, 20 percent of
patients were considered responders because they demonstrated no tumor growth on
octreotide, whereas tumor growth was documented prior to starting octreotide. It there-
fore appears as a single agent octreotide will be oflimited utility.
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Increasingly, patients with metastatic endocrine tumors are being evaluated for hep-
atic transplantation. With increased ability to stage metastatic disease with octreotide
scanning and other localization studies, it may be that a subset of patients can be identi-
fied where this procedure will be ofvalue in the future.
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